-+ 0.00%
-+ 0.00%
-+ 0.00%

IVONESCIMAB MONOTHERAPY DEMONSTRATES STATISTICALLY SIGNIFICANT OVERALL SURVIVAL BENEFIT COMPARED TO PEMBROLIZUMAB MONOTHERAPY IN PD-L1-POSITIVE ADVANCED NSCLC IN HARMONI-2 STUDY CONDUCTED BY AKESO IN CHINA

路透·09/02/2026 21:41:12

登录查看新闻详情